Hematological malignancies associated with FGFR1 rearrangements (8p11-chromosome eighth-myeloproliferative syndrome (EMS) are rare atypical chronic myeloproliferative disorders that are in most cases associated with eosinophilia and T-cell proliferation. Clinically, EMS is an aggressive disease with a short chronic phase leading to rapid transformation into acute myeloid leukemia. The only effective treatment to date is allogenic stem cell transplantation. The genetic hallmark of this pathology is a recurrent chromosomal 8p11 rearrangement that fuses the tyrosine kinase domain of the fibroblast growth factor receptor 1 gene (FGFR1) to different gene partners. To date, nine FGFR1 partners have been identified in patients with EMS: ZMYM2/ZNF198 at 13q12, FGFR1OP/FOP at 6q27, CEP110/ CEP1 at 9q33, BCR at 22q11, FGFR1OP2 at 12p11, TRIM24/ TIF1 at 7q34, MYO18A at 17q23, CPSF6 at 12q15 and a human endogenous retroviral sequence, HERV-K at 19q13.3. Here, we report the identification of a tenth FGFR1 partner gene in a case of EMS associated with a t(2;8)(q37;p11) translocation.
The patient, an 82-year-old man, was referred to our department in May 2002 for pancytopenia with hemoglobin level of 10 g per 100 ml, a white blood cell count of 2.4 Â 10 9 /l and a platelet count of 40 Â 10 9 /l. Bone marrow aspiration showed a refractory anemia with an excess of blasts (15%). Cytogenetical analysis was not performed at that time. Between 2002 and 2007, the white blood cell count remained stable and the patient was occasionally treated with red blood cell transfusion depending on the hemoglobin levels (see Table 1 for evolution of blood counts). In September 2007, the white blood cell count increased to 20 Â 10 9 /l with 10% eosinophils, 2-4% myelocytes and metamyelocytes, and 8% circulating blasts. Bone marrow aspiration was hypocellular with moderate dysgranulopoiesis and 15% blasts. The presence of dacryocytes on blood smears suggested some degree of myelofibrosis. In May 2008, a new blood count showed a decrease in hemoglobin levels (8 g per 100 ml) and a stable white blood cell count with an increase in blasts (42%), attesting to the transformation into acute myeloid leukemia. Supportive care with red blood cell transfusions permitted outpatient care at first, but the patient died 1 year later.
The karyotype, as performed on bone marrow cells in September 2007, was interpreted as follows: 46,XY,t(2;8)(q37;p11) [20] ( Figure 1a ). Conventional cytogenetic analysis on patient blood lymphocytes revealed a normal karyotype, confirming that the t(2;8)(q37;p11) translocation was acquired, and suggesting the diagnosis of EMS. A fluorescence in situ hybridization experiment with BAC RP11-333B24 as a probe spanning the FGFR1 locus confirmed the expected gene rearrangement (Figure 1b) . To identify the derivative chromosome der(2) breakpoint, fluorescence in situ hybridization experiments were performed with a series of BAC clones covering chromosomal band 2q37. A split signal was observed for the BAC RP11-497D24 indicating that it contained the chromosome 2 breakpoint (Figure 1b) . Furthermore, retrospective analysis by fluorescence in situ hybridization using BACs RP11-333B24 and RP11-497D24 on bone marrow smears performed in 2002 revealed two normal signals for each BAC (data not shown), indicating that the t(2;8) translocation was a secondary event acquired at the time of transformation into acute myeloid leukemia.
The 2q37 BAC RP11-497D24 harbors two genes in the same orientation as FGFR1 (5 0 centromereF3 0 telomere): LRRFIP1 and RAMP1. As all FGFR1 fusion genes reported to date share the feature of contributing their 5 0 portion to the fusion joined by the 3 0 of FGFR1, and because the LRRFIP1 5 0 part was coding for an N-terminal coiled-coil domain, as in many FGFR1 partners, we hypothesized that LRRFIP1 was a more likely candidate partner for an in-frame fusion with FGFR1. Thus, we performed reverse transcription-PCR with specific primers designed to amplify a putative LRRFIP1-FGFR1 fusion transcript. Total RNA was extracted from patient bone marrow cells and reverse transcribed using random hexamers and Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). We obtained specific amplification of the putative fusion transcript from cDNA with the following design: as all FGFR1 fusions described show a genomic breakpoint close to exon 9, we performed reverse transcription-PCR using several forward primers located in the LRRFIP1 reference sequence (NM_004735.2) and one reverse primer located in exon 10 of FGFR1 (FGFR1ex10: 5 0 -ACAGCCACTTTGGTCACACGGT-3 0 ). A specific fragment was detected using a forward primer located in exon 4 of LRRFIP1 (LRRex4: 5 0 -AGACGAGCGCATGTCAGTGGGTAGT-3 0 ), which was not amplified in U937 control cells (Figure 2a,  lanes 1 and 4) . Sequence analysis of the PCR product revealed the in-frame fusion of LRRFIP1 exon 9 with FGFR1 exon 9 ( Figure 2b ). As public sequence databases contain an alternative transcript for LRRFIP1 that has coding potential for a highly divergent protein (ENST00000308482, at the Ensembl Genome database), we performed reverse transcription-PCR using a primer that is located in this alternative sequence but is absent . RP11-333B24 hybridization shows one normal signal on a chromosome 8 (arrow), one signal on chromosome der2 (arrow head) and one signal on chromosome der 8 (asterisk). RP11-497D24 hybridization gives one normal signal on a chromosome 2 (arrow), one signal on chromosome der2 (arrow head) and one signal on chromosome der8 (asterisk). Letters to the Editor partner. LRRFIP1 is ubiquitously expressed and encodes for a protein found in the nuclear and cytoplasmic compartments. The LRRFIP1 protein has multiple and complex functions. In the nucleus, it acts as a transcriptional repressor that decreases the expression of the epidermal growth factor receptor 1 and of the platelet-derived growth factor a-chain.
2 LRRFIP1 was also recently identified as the first repressor to directly regulate the tumor necrosis factor-a promoter. 3 In the cytoplasm, through its N-terminal coiled-coil domain, LRRFIP1 interacts with the leucine-rich repeat (LRR) region of the Flightless-1 protein, which belongs to the gelsolin family of actin-binding proteins. Finally, LRRFIP1 contains a lysine-rich motif that binds to the TAR RNA element present at the 5 0 end of human immunodeficiency virus-1 viral transcripts.
The LRRFIP1-FGFR1 transcript sequence encodes a predicted chimeric protein of 668 amino acids, containing the N-terminal coiled-coil domain of LRRFIP1 and the two tyrosine kinase domains of FGFR1 (Figure 3) . The presence of the coiled-coil domain may induce the dimerization of LRRFIP1-FGFR1, thus leading to the constitutive activation of the kinase domains. By this mechanism, LRRFIP1-FGFR1 may promote cellular transformation as shown earlier for other FGFR1 fusions, 4,5 thus representing a possible specific target for therapy.
Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity Many specific leukemia subtypes have been identified by characteristic and reproducible phenotypic features detected mainly by cytomorphology and immunophenotyping. Further research then led to unraveling recurring cytogenetic and molecular genetic aberrations forming the pathogenetic basis of the respective entities as exemplified by chronic myelogenous leukemia. 1, 2 We here report on 20 cases with acute myeloid leukemia (AML) with limited differentiation as identified by their specific immunophenotype. All of these cases were shown to carry an NPM1 type A mutation.
Out of a nonselected cohort of 1094 AML at diagnosis we detected 20 cases that could be identified based primarily on their specific and unusual immunophenotype comprising 
